52 results on '"Suh, Cheolwon"'
Search Results
2. Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features
3. Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities
4. Feasibility of heart transplantation for patients with amyloid cardiomyopathy accompanying extracardiac organ involvement
5. A Prospective, Multicenter Phase II Study of Consolidation with Cyclophosphamide, Bortezomib and Dexamethasone (CVD) in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation; The KMM130 Study
6. Clinicopathologic characteristics and clinical outcome of multiple myeloma with del(17p): A retrospective analysis of single center experience for 12 years.
7. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
8. Phase II Brentuximab Vedotin Trial for Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas
9. Bortezomib-Melphalan-Prednisone (VMP) Versus MP as Initial Treatment for Very Elderly Patients With Newly Diagnosed Multiple Myeloma
10. The outcomes of Korean Patients With Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160)
11. Clinical Features and Survival of Patients With Follicular Lymphoma in Korea
12. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
13. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non–Small-Cell Lung Cancer After Curative Resection
14. Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma
15. A case of ALK negative anaplastic large cell lymphoma with leukaemic manifestation, transformed from CD4 positive T-cell large granular lymphocytic leukaemia
16. LGALS3 as a prognostic factor for classical Hodgkin's lymphoma
17. Outcomes and prognostic factors of patients with lung cancer and pneumonia-induced respiratory failure in a medical intensive care unit: A single-center study
18. High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma
19. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
20. MET and MST1R as prognostic factors for classical Hodgkin's lymphoma
21. JAK2 mutation-negative secondary erythrocytosis in multiple myeloma: a case report follow up
22. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial
23. Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma
24. Development of subsequent bloodstream infection in patients with positive Hickman catheter blood cultures and negative peripheral blood cultures
25. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: A single center comparative analysis of efficacy and toxicity
26. Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report
27. Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia
28. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis
29. Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation
30. Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study
31. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the extracranial head and neck region: A high rate of dissemination and disease recurrence
32. A Phase II Study of Erlotinib as a First-Line Therapy for Patients with Non—Small-Cell Lung Cancer with Favorable Clinical Predictors
33. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as a First-Line Therapy for Never-Smokers with Adenocarcinoma of the Lung and Asymptomatic Synchronous Brain Metastasis
34. Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma
35. P1-220: A phase I and pharmacologic study of Belotecan in combination with Cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
36. P3-142: Epidermal growth factor receptor (EGFR) and KRAS mutations in non-small cell lung cancer (nsclc) patients treated with gefit-inib
37. PD4-1-7: Consolidation chemotherapy with monthly Paclitaxel and Cisplatin (PC) or observation after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLS): Randomized phase II study
38. A1-01: Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized phase III trial
39. P2-189: Neoadjuvant weekly paclitaxel/cisplatin chemotherapy (WPC) with concurrent thoracic radiation (TR) followed by surgical resection (S) for pathologically proven N2 (pN2) stage IIIA non-small cell lung cancer (NSCLC): phase II study
40. P3-141: Assessments of the epidermal growth factor receptor mutations and amplification and their clinical implication in patients with lung adeno-carcinoma
41. New Staging Systems Can Predict Prognosis of Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation as First-Line Therapy
42. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non–small-cell lung cancer
43. Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer
44. P-584 Severe radiation pneumonitis after concurrent chemoradiation therapy in locally advanced non-small cell lung cancer: Risk factors and the prognosis
45. P-166 The significance of clinically staged bilateral mediastinal or supraclavicular adenopathy in patients with stage N3 non-small cell lung cancer
46. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields
47. 18 A multi-center, phase II clinical trial of genexol(paclitaxel) and cisplatin in patients with non-small cell lung cancer
48. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non–small-cell lung cancer
49. Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC)
50. Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.